A personalized cancer vaccine, built from a patient’s own tumor, cut the risk of melanoma coming back or causing death by 42 percent in a major new trial.
Quick Take
- A Phase 3 trial called INTerpath-001 tested the mRNA vaccine V940 alongside the drug pembrolizumab in patients with surgically removed, high-risk melanoma.
- Patients getting the vaccine plus pembrolizumab had a 42 percent lower relative risk of recurrence or death than those getting pembrolizumab alone.
- The combination also cut the spread of cancer to distant body parts by 38 percent compared with pembrolizumab alone.
- Earlier Phase 2 testing of the same approach showed a 49 percent reduction in recurrence risk after five years of follow-up.
- Merck and Moderna, the companies behind the vaccine, have not yet shown whether it extends overall survival.
What The Trial Actually Tested
The study, known as INTerpath-001, enrolled patients with stage IIB through stage IV melanoma who had already had their tumors surgically removed. Doctors split them into two groups. One group got the experimental vaccine, called intismeran autogene or V940, combined with pembrolizumab, sold under the brand name Keytruda. The other group received pembrolizumab alone. Neither patients nor doctors knew which treatment a person received.
After a median follow-up of just over two years, researchers found the vaccine group had a hazard ratio of 0.58 for recurrence or death. That number translates into a 42 percent relative risk reduction, a result strong enough to clear the trial’s statistical bar with high confidence. The same group also saw a 38 percent drop in cancer spreading to distant organs, another sign the treatment is doing real work against the disease.
How The Vaccine Is Built For Each Patient
Unlike a traditional vaccine made the same way for everyone, V940 is custom-built. Scientists sequence a patient’s own tumor tissue, then use that genetic blueprint to design a shot aimed at the specific mutations driving that person’s cancer. The goal is to train the immune system to hunt down cancer cells that still resemble the original tumor, lowering the odds it returns after surgery.
This individualized model builds on earlier Phase 2 data from the same partnership. In that smaller study, patients followed for five years showed a 49 percent reduction in recurrence or death and a 59 percent drop in distant spread when the vaccine was paired with pembrolizumab. The new Phase 3 results, while measured over a shorter two-year window, point in the same direction and came from a much larger group of patients.
Why Doctors Are Watching Closely, Not Celebrating Yet
Both trial arms received pembrolizumab, a drug already approved and widely used for melanoma. That design means the 42 percent figure measures the vaccine’s added benefit on top of existing treatment, not the vaccine working alone. This distinction matters for doctors deciding how to weigh the new therapy against what they already prescribe.
The companies have not yet released full survival data showing whether patients actually live longer, as opposed to simply going longer without their cancer returning. Those two outcomes often move together in melanoma, but they are not identical, and regulators typically want to see both before granting broad approval.
Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase III Trial
Phase III findings suggest that tumor-specific #mRNA vaccines could improve outcomes for patients with high-risk #melanoma following surgery@moderna_tx @Merckhttps://t.co/E1wA59DwiX
— Inside Precision Medicine (@Inside_PM) October 26, 2026
Because each dose is custom-made from a patient’s own tumor, questions about manufacturing speed, cost, and access remain open. Personalized therapies like this one require tumor sequencing and lab production before a single shot can be given, a process that adds time and expense compared with off-the-shelf treatments. How Merck and Moderna scale that process will shape how many patients can actually benefit once any approval comes through.
What Happens Next
Merck and Moderna are continuing to follow patients in the trial and plan to report longer-term outcomes, including survival data, as more time passes. A related study, INTerpath-002, is already testing the same vaccine combination in other cancer settings, suggesting the companies see this result as a foundation rather than a finish line. For now, melanoma patients and their doctors have a genuinely encouraging new data point, built on a real, randomized trial rather than early-stage hope.
Sources:
merck.com, dermatologytimes.com
